Lundbeck has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for Lu AH69593, its investigational oral orexin 2 receptor agonist being developed to treat narcolepsy, a chronic neurological disorder that affects the brain’s ability to regulate sleep and wakefulness.
The designation marks an important regulatory milestone for the Danish pharmaceutical company as it advances the experimental therapy through clinical development. Lu AH69593 is currently being evaluated in a Phase 1b clinical trial and is the lead candidate in Lundbeck’s portfolio of investigational medicines targeting sleep-wake disorders.
The FDA’s Fast Track program is intended to accelerate the development and review of therapies designed to treat serious medical conditions while addressing significant unmet medical needs. The designation allows companies to work more closely with the agency throughout the development process and may enable faster regulatory review if the therapy demonstrates positive clinical results.
Narcolepsy is a lifelong neurological condition that significantly disrupts normal sleep and wake cycles. Patients often experience overwhelming daytime sleepiness, sudden episodes of falling asleep, disrupted nighttime sleep, sleep paralysis, and vivid hallucinations when falling asleep or waking up. People diagnosed with narcolepsy type 1 may also experience cataplexy, a sudden and temporary loss of muscle control that is frequently triggered by strong emotions such as laughter, excitement, or surprise.
Although several treatments are available to help manage symptoms, many patients continue to struggle with excessive daytime sleepiness and impaired daily functioning, highlighting the need for new treatment approaches.
Lundbeck’s investigational therapy targets the orexin pathway, which plays a critical role in maintaining wakefulness. Orexin is a naturally occurring neuropeptide produced in the brain that helps regulate arousal, alertness, and the transition between sleep and wakefulness.
In people with narcolepsy, particularly type 1, disruption of orexin signaling is considered one of the primary causes of the disorder. Lu AH69593 has been designed to activate the orexin 2 receptor (OX2R), which is regarded as a key component of the brain’s wake-promoting system.
By stimulating this receptor, the therapy aims to restore more normal wakefulness and improve sleep-wake regulation, potentially addressing the underlying biology of narcolepsy rather than simply treating its symptoms.
Lundbeck believes the investigational medicine has the potential to become a best-in-class oral orexin 2 receptor agonist.
Johan Luthman, Executive Vice President and Head of Research and Development at Lundbeck, said the FDA’s decision represents an important step forward for both the company’s research program and patients living with narcolepsy.
“Fast Track designation is an important milestone for Lu AH69593 and for our ambition to translate compelling orexin biology into a new treatment approach for narcolepsy and other sleep-wake disorders,” Luthman said.
He noted that maintaining wakefulness affects nearly every aspect of daily life for people living with narcolepsy, including education, employment, and social interactions.
“The designation underscores the urgent need for innovative therapies for narcolepsy and recognizes the potential of Lu AH69593,” he added. “We are encouraged by the opportunity to work closely with the FDA as we continue advancing the program.”
According to Lundbeck, the therapy also reflects the company’s broader strategy of expanding its research pipeline in neurology, neuroendocrine disorders, and rare diseases by developing treatments that target the biological mechanisms underlying disease.
The Fast Track designation does not indicate that the medicine has been proven safe or effective, but it provides an opportunity for more frequent interactions with the FDA during development. The designation may also allow the company to submit sections of a future regulatory application on a rolling basis and potentially qualify for priority review if the required criteria are met.
As Lu AH69593 continues through early clinical testing, Lundbeck hopes the therapy could eventually provide a new treatment option for people living with narcolepsy, offering improved wakefulness by targeting one of the disease’s fundamental biological pathways.